Richard D. Baird

11.7k total citations · 1 hit paper
87 papers, 3.5k citations indexed

About

Richard D. Baird is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Richard D. Baird has authored 87 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 43 papers in Pulmonary and Respiratory Medicine and 30 papers in Cancer Research. Recurrent topics in Richard D. Baird's work include Advanced Breast Cancer Therapies (28 papers), Cancer Genomics and Diagnostics (20 papers) and Cancer Treatment and Pharmacology (20 papers). Richard D. Baird is often cited by papers focused on Advanced Breast Cancer Therapies (28 papers), Cancer Genomics and Diagnostics (20 papers) and Cancer Treatment and Pharmacology (20 papers). Richard D. Baird collaborates with scholars based in United Kingdom, United States and Spain. Richard D. Baird's co-authors include Carlos Caldas, Javier García-Corbacho, Simon Pacey, Florent Moulière, Nitzan Rosenfeld, James D. Brenton, Charles Massie, Jonathan C. M. Wan, Stan B. Kaye and Johann S. de Bono and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and Cancer Research.

In The Last Decade

Richard D. Baird

83 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Liquid biopsies come of age: towards implementation of circulating tumour DNA

2017 1.8k citations Javier García-Corbacho, Florent Moulière et al. profile →

Peers

Countries citing papers authored by Richard D. Baird

Since Specialization

Citations

This map shows the geographic impact of Richard D. Baird's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard D. Baird with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard D. Baird more than expected).

Fields of papers citing papers by Richard D. Baird

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard D. Baird. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard D. Baird. The network helps show where Richard D. Baird may publish in the future.

Co-authorship network of co-authors of Richard D. Baird

This figure shows the co-authorship network connecting the top 25 collaborators of Richard D. Baird. A scholar is included among the top collaborators of Richard D. Baird based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard D. Baird. Richard D. Baird is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adaptive enrichment trial designs using joint modelling of longitudinal and time-to-event data 2024 ·Statistical Methods in Medical Research ·(unknown), Richard D. Baird, Thomas Jaki	0
2	Discriminating subtypes in advanced breast cancer with ctDNA methylation profiling. 2024 ·Journal of Clinical Oncology ·(unknown), Ros Cutts, (unknown), Sarah Hrebien, Aditi Gulati, Qiong Gao, Syed Haider, Rebecca Roylance, Andrew Tutt, Richard D. Baird, Iain R. Macpherson, Alistair Ring, Stephen Johnston, Alicia Okines, Isaac García-Murillas, Sarah Filippi, Nicholas C. Turner	0
3	A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms 2024 ·Experimental Biology and Medicine ·Nahid Zareian, Oleg Eremin, Hardev Pandha, Richard D. Baird, Vineet Kwatra, (unknown), (unknown), (unknown), (unknown), (unknown), Adrian J. Shepherd, Dileep N. Lobo, Jennifer Eremin, Farzin Farzaneh, Shahram Kordasti, James Spicer	2
4	Early phase clinical trials in oncology: Realising the potential of seamless designs 2023 ·European Journal of Cancer ·Thomas Jaki, (unknown), (unknown), Pavel Mozgunov, Haiyan Zheng, Richard D. Baird	7
5	A Road Map for Designing Phase I Clinical Trials of Radiotherapy–Novel Agent Combinations 2022 ·Clinical Cancer Research ·Sarah Brown, Samantha Hinsley, Emma Hall, Chris Hurt, Richard D. Baird, Martin Förster, Andrew Scarsbrook, Richard Adams	4
6	Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA 2021 ·Genome Research ·Irena Hudecova, Christopher G. Smith, Robert Hänsel‐Hertsch, Chandra Sekhar Reddy Chilamakuri, James A. Morris, (unknown), Katrin Heider, Dineika Chandrananda, Wendy N. Cooper, Davina Gale, Javier García-Corbacho, Simon Pacey, Richard D. Baird, Nitzan Rosenfeld, Florent Moulière	58
7	278MO cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients 2020 ·Annals of Oncology ·(unknown), (unknown), Iurie Bulat, (unknown), (unknown), H-T. Arkenau, Richard D. Baird, Andrew Wardley, Rebecca Roylance, (unknown), (unknown), Tao Wan, Andrew P. Beelen, Jessica A. Sorrentino	4
8	Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA 2019 ·Genome Medicine ·Meiling Gao, Maurizio Callari, Emma Beddowes, Stephen‐John Sammut, Marta Grzelak, Heather Biggs, Linda Jones, Abdelhamid Boumertit, Sabine C. Linn, Javier Cortés, Mafalda Oliveira, Richard D. Baird, Suet‐Feung Chin, Carlos Caldas	34
9	A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer 2018 ·Clinical Cancer Research ·Erika Hamilton, Manish R. Patel, Anne Armstrong, Richard D. Baird, Komal Jhaveri, Matthias Hoch, Teresa Klinowska, Justin P.O. Lindemann, Shethah Morgan, Gaia Schiavon, Hazel M. Weir, Seock‐Ah Im	67
10	An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours 2018 ·European Journal of Cancer ·Hendrik‐Tobias Arkenau, Antoîne Italiano, Gabriel Mak, Maud Toulmonde, Richard D. Baird, Javier García-Corbacho, Ruth Plummer, Michael Flynn, Martin Förster, Richard H. Wilson, Diégo Tosi, Antoine Adenis, (unknown), John Posner, (unknown), Akinori Arimura, Sanjeev Deva, James Spicer	10
11	PIONEER- Pre-operative wIndOw study of letrozole plus PR agonist megestrol acetate versus letrozole aloNE in post-menopausal patients with ER-positive breast cancer 2017 ·Annals of Oncology ·Sanjeev Kumar, (unknown), (unknown), Linda Jones, W. Qian, Elena Provenzano, Carlos Caldas, Pan Pantziarka, Jason S. Carroll, Richard D. Baird	1
12	Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation 2016 ·Molecular Cancer Therapeutics ·Joo Ern Ang, (unknown), (unknown), Yasmin J. Asad, Alan T. Henley, Melanie Valenti, Gary Box, Alexis de Haven Brandon, Richard D. Baird, Lori S. Friedman, Mika K. Derynck, Bart Vanhaesebroeck, Suzanne A. Eccles, Stan B. Kaye, Paul Workman, Johann S. de Bono, Florence I. Raynaud	16
13	Interim results from the completed first-in-human phase I dose escalation study evaluating MP0250, a multi-DARPin® blocking HGF and VEGF, in patients with advanced solid tumors 2016 ·Annals of Oncology ·Mark R. Middleton, (unknown), Sanjeev Kumar, (unknown), Jordi Rodón, Karin H. Herbschleb, J. A. Steiner, Christof Zitt, Daniel Feurstein, Sabrina Schreiner, (unknown), Keith M. Dawson, (unknown), (unknown), Michael T. Stumpp, A. Harstrick, Richard D. Baird, Aurelius Omlin	4
14	A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors 2013 ·Clinical Cancer Research ·Balaji Venugopal, Richard D. Baird, Rebecca Kristeleit, Ruth Plummer, Richard Cowan, Adam Stewart, Nele Fourneau, Peter Hellemans, Yusri Elsayed, (unknown), Johan W. Smit, Ann Forslund, Charles E. Phelps, A. John Camm, T.R. Jeffry Evans, Johann S. de Bono, Udai Banerji	97
15	Genetic heterogeneity in breast cancer: the road to personalized medicine? 2013 ·BMC Medicine ·Richard D. Baird, Carlos Caldas	39
16	Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials 2011 ·Clinical Cancer Research ·David Olmos, Richard D. Baird, Timothy A. Yap, Christophe Massard, Lorna Pope, Shahneen Sandhu, Gerhardt Attard, Juliet Dukes, Dionysis Papadatos-Pastos, (unknown), Stan B. Kaye, Johann S. de Bono	21
17	An analysis of the risk of toxicity associated with participation in phase 1 oncology trials of novel molecularly targeted agents (mta) at the drug development unit, royal marsden hospital 2010 ·Annals of Oncology ·(unknown), (unknown), David Olmos, (unknown), M. Puglisi, Leonardo Trani, Debashis Sarker, Montserrat Blanco, Richard D. Baird, R. Molife	5
18	Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors 2009 ·Molecular Cancer Therapeutics ·Richard D. Baird, Jos Kitzen, Paul A. Clarke, André Planting, (unknown), Alison Reid, (unknown), Luis López Lázaro, Begoña de las Heras, Ian Judson, Stan B. Kaye, Ferry A.L.M. Eskens, Paul Workman, Johann S. de Bono, Jaap Verweij	33
19	ES-285, a novel marine anticancer agent: Investigation of mechanism of action using gene expression microarrays 2005 ·Cancer Research ·Richard D. Baird, Paul A. Clarke, Paul Workman	5
20	Drug resistance reversal—are we getting closer? 2003 ·European Journal of Cancer ·Richard D. Baird, Stan B. Kaye	111

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact